Beyfortus Deadly RSV Monoclonal AB Shots for Infants, Other [Genetic] Treatments Close Behind.

Up your arm and other places, to keep you safe!

Rephrasing the old movie line, “if they keep saying ‘safe and effective, protect, public health’ — it means they’re going to kill you. Run!”

The case at hand — “French Researchers Identify ‘Improbably High Rate of Deaths’ in Newborns Who Received New RSV Shot” (Children’s Health Defense, 2024.01.02):

In interviews with The Defender, the researchers — French independent scientist and author Hélène Banoun, Ph.D., and French statistician Christine Mackoi — explained that data from France’s National Institute of Statistics and Economic Studies (INSEE) indicates an improbably high rate of deaths of babies between 2 and 6 days old in France during September and October 2023. This increase, the researchers said, coincides with the introduction of Beyfortus in French hospitals, which began on Sept. 15, 2023.

In an interview with cardiologist Peter McCullough, M.D., MPH, Banoun said that over 200,000 newborn babies in France have been injected with Beyfortus since that date.

A study published in the New England Journal of Medicine (NEJM) on Dec. 28 concluded, “Nirsevimab protected infants against hospitalization for RSV-associated lower respiratory tract infection and against very severe RSV-associated lower respiratory tract infection in conditions that approximated real-world settings.” Beyfortus was developed jointly by AstraZeneca and Sanofi. The safety study was, accordingly, also funded by AstraZeneca and Sanofi. According to Banoun, official data do not indicate that Beyfortus is effective. The data do, however, indicate a high prevalence of adverse reactions — including bronchiolitis — even though the treatment is supposed to protect recipients from respiratory illness. “The most frequently reported adverse events are upper respiratory tract infections, including bronchiolitis,” she said.

According to the INSEE data, 54 deaths were recorded for 55,489 births in France in September 2023, despite the average number of expected deaths being 38, based on historical averages. For October 2023, the data showed 61 deaths out of 57,940 births, despite the average number of expected deaths being 40.

Here are the stats for neonatal death rates in France, split by early, late and post neonatal deaths:

The 2-6 days neonatal mortality seems to be 0.75/3.63 = 20.7% of the total neonatal mortality, or about1/5 of the total neonatal mortality. There has been about a 50% increase in [2-6 days] neonatal deaths in France since the introduction of the Beyfortus shot for the newborns, or about 50%*1/5 = 10% increase in the overall neonatal mortality in France.

Regardless of these atrocious results and huge safety red flags, Beyfortus RVS shots have been embraced worldwide. The CDC recommended Beyfortus in August 2023, while the European Medicines Agency (EMA) authorized the drug in September 2022. Health Canada approved BEYFORTUS™ (nirsevimab) for the prevention of RSV disease in infants on Apr. 24, 2023.

What does it mean for the US in terms of infant mortality going forward? “US infant mortality rate rises for first time in more than 20 years” (CNN, 2023.11.01):

The year before, in 2021, an analysis from the US Centers for Disease Control and Prevention found that while the total number of infant deaths had increased from 2020, the mortality rate had remained the same—at 5.44 deaths per 1,000 live births.

The new report, citing provisional data, found the rate rose to 5.60 infant deaths per 1,000 births, corresponding with 20,538 <1 year old deaths in 2022.

If that number were to grow by 10%, as in France, that would be extra 2,054 deaths in <1 year olds in the US. Which means, the US is looking at potentially about 2,054 additional newborn deaths next year due to the introduction of Bayfortus newborn jabs alone.

According to a previous CDC study, there were grand total of 300 infant deaths attributed to RSV in 2005-2016 period in the US (not per year - the total for the whole 11 years!):

Closer to the regulatory approval of the Beyfortus jab in the US, the updated “Mortality Associated With Influenza and Respiratory Syncytial Virus in the US, 1999-2018” (JAMA Network, 2022.02,28), in 1999-2018 in the US there were about 96 underlying respiratory deaths associated with RSV annually in <1 year olds, and additional 20 RSV deaths per year in 1-4 year olds:

How this estimate grew so much in one year (from 2021 to 2022) is beyond me. But let us even go with the latest numbers from the Covid-era “unbiased” science reports.

By the most conservative estimates, the benefit of Beyfortus nirsevimab shots would be killing about 2,054 newborns in the US per year to maybe prevent around 26-96 RVS deaths, if 100% effective…

The estimates are conservative because the French authors only accounted for the immediate neonatal mortality in 2-6 days after a live birth. The actual total death count caused by Beyfortus shot alone is most likely much higher when the subsequent neonatal days 7-364 will be taken into account. It’s just that we are not that far out yet from the start of Beyfortus administration in France to be able to see the complete fallout.

And this is just for starters, as Pfizer also has a novel, just approved RSV “vaccine” for administration to pregnant individuals (“U.S. FDA Approves ABRYSVO™, Pfizer’s Vaccine for the Prevention of Respiratory Syncytial Virus (RSV) in Infants Through Active Immunization of Pregnant Individuals 32-36 Weeks of Gestational Age”):

FDA's vaccine advisory committee (VRBPAC) votes to approve Pfizer's RSV drug in pregnant women with a 10:4 split. 4 new temp members appeared yesterday and all voted to approve.

And this is only the tip of the “vaccine” iceberg lumbering our way. “What’s Next for mRNA Vaccines?” (GEN Edge, 2022.08.29):

Moderna mRNA vaccines are already in the works to reduce the health risks of latent viruses like Epstein-Barr virus (EBV) and cytomegalovirus (CMV) and to tackle additional areas of unmet need, including an all-in-one mRNA vaccine to treat COVID-19, seasonal flu, and respiratory syncytial virus (RSV). Additionally, Moderna plans to develop mRNA vaccines to help patients beat Herpes simplex virus (HSV), MS, cancer, and HIV once and for all.

“Once and for all” sounds about right.

And if that isn’t enoughfor jab enthusiasts, the WHO has a “vaccine” development plan as well. “WELCOME TO THE WHO VACCINE TRIAL TRACKER”:

And, the EU doesn’t want to be left behind either:

“Vaccelerate!”: German-EU Programme Aims to Facilitate Fast-Vax For “Next Pandemic”

Now we really can rest assured that they want to keep us safe.